# Balstilimab

Source: https://onco.cc/drugs/balstilimab/  
OnCo record `balstilimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.

## Summary

Balstilimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Agenus Inc. and ImmunoGenesis, in colorectal cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: AGEN2034
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Balstilimab: https://clinicaltrials.gov/search?intr=Balstilimab

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [Agenus](https://onco.cc/companies/agenus/)
- trials: [A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer](https://onco.cc/trials/nct05608044/), [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers](https://onco.cc/trials/nct05205330/)

---
JSON: https://onco.cc/api/v1/entities/balstilimab.json